| Sonja Thurman, | |
|
206 Maryland Ave, Mccomb, MS 39648-3926 | |
| (601) 250-4815 | |
| (601) 250-6859 |
| Full Name | Sonja Thurman |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 206 Maryland Ave, Mccomb, Mississippi |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104033778 | NPI | - | NPPES |
| 04802313 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | S3072 (Mississippi) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Sonja Thurman, 834 Highway 12 W, #105, Starkville, MS 39759-3582 Ph: (601) 250-4815 | Sonja Thurman, 206 Maryland Ave, Mccomb, MS 39648-3926 Ph: (601) 250-4815 |
News Archive
Ever wondered what happens inside your brain when you stay awake for a day, a night and another day, before you finally go to sleep? In a new study published today in the journal Science, a team of researchers from the University of Liege and the University of Surrey have scanned the brains of 33 participants across such a 2-day sleep deprivation period and following recovery sleep.
In the May 3 issue of the Journal of the American Medical Association, Brian L. Strom, MD, MPH, Professor of Public Health and Preventive Medicine and Chair of the Department of Biostatistics and Epidemiology at the University of Pennsylvania School of Medicine, analyzes the limitations of the current system of drug-safety monitoring and proposes a solution that addresses overly aggressive early marketing practices
A research group led by Osaka University and the University of Tokyo found that the intracellular protein trafficking is important for higher brain functions such as learning and memory. The research group showed that a molecule, ARHGAP33 regulates synaptic functions and behaviors via intracellular protein trafficking and that the lack of ARHGAP33 causes neuropsychiatric disorder-related impaired higher brain functions.
Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces that the first patients have been dosed in the United States in a global Phase 3 clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). The first patient was dosed on July 22, 2014.
› Verified 5 days ago
Laura Kathryn Price, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1115 Parklane Dr Ste 308, Mccomb, MS 39648 Phone: 601-810-3705 Fax: 877-236-7977 | |
Anna Jones Lambert, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 114 Main St, Mccomb, MS 39648 Phone: 601-249-2515 Fax: 601-684-7395 | |
Felicia Skipper, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 206 Maryland Ave, Mccomb, MS 39648 Phone: 601-250-4815 Fax: 601-250-6859 | |
Felicia Murrah, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 206 Maryland Ave, Mccomb, MS 39648 Phone: 601-250-4815 Fax: 601-250-6859 | |
Terri Anne Clements, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 318 Kendall Ave, Mccomb, MS 39648 Phone: 601-600-2633 Fax: 601-385-1626 | |
Kyla Bland, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 206 Maryland Ave, Mccomb, MS 39648 Phone: 601-847-7040 |